Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

290
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
290
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

482
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
482
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

276
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
276
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

274
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
274
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

523
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
523
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

304
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Approach to Globus Sensation: Clinical Pearls for Clinicians.

Mayo Clinic proceedings·2026
Same author

Cost-effectiveness of Microbiota Restoration Therapies for Recurrent Clostridioides difficile Infection.

The American journal of gastroenterology·2026
Same author

When Does Clostridioides difficile "Recur"? Reconcile Epidemiologic & Bedside Recurrent CDI definitions.

The Journal of infectious diseases·2026
Same author

Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1b Esophageal Adenocarcinoma: A Patient-Level Pooled Analysis of International Studies.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study.

Lancet regional health. Americas·2026
Same author

Risk of Solid Organ Transplantation in Individuals With Celiac Disease: A Nationwide Cohort Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Nov 9, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Medication use and microscopic colitis: a multicentre retrospective cohort study.

Haley M Zylberberg1, Amrit K Kamboj2, Nicole De Cuir3

  • 1Division of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.

Alimentary Pharmacology & Therapeutics
|April 14, 2021
PubMed
Summary

Nonsteroidal anti-inflammatory drug (NSAID) use is linked to microscopic colitis (MC). However, proton pump inhibitors (PPIs), H2 blockers, and oral diabetes medications show an inverse association with MC risk.

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.3K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.2K

Related Experiment Videos

Last Updated: Nov 9, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.3K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.2K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Medication use is a suspected factor in microscopic colitis (MC) development.
  • Previous studies on medication and MC have yielded inconsistent results.
  • Variations in study designs may contribute to conflicting findings.

Purpose of the Study:

  • To investigate the association between specific medication use and the incidence of microscopic colitis.
  • To clarify the role of common drug classes in MC etiology.

Main Methods:

  • A case-control study was conducted involving 344 patients with biopsy-proven MC and 668 controls with diarrhea but negative MC biopsies.
  • Data on demographics, medication use (including NSAIDs, PPIs, H2 blockers, oral diabetes medications), smoking, and celiac disease were collected over a 10-year period.
  • Conditional logistic regression was employed for analysis, with and without adjustment for smoking.

Main Results:

  • Nonsteroidal anti-inflammatory drug (NSAID) use was positively associated with MC (OR 1.63; 95% CI 1.12-2.38).
  • Proton pump inhibitors (PPIs) (OR 0.64; 95% CI 0.47-0.87), H2 blockers (OR 0.46; 95% CI 0.24-0.88), and oral diabetes medications (OR 0.47; 95% CI 0.27-0.81) showed an inverse association with MC.
  • These associations remained significant after adjusting for smoking.

Conclusions:

  • NSAID use is associated with an increased risk of microscopic colitis.
  • Use of PPIs, H2 blockers, and oral diabetes medications appears to be inversely related to MC risk.
  • The use of a diarrhea-control group, rather than healthy controls, may explain the observed inverse associations and is recommended for future studies on drug-induced MC.